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Abstract
Background: The clinical results of in vitro fertilization of slowly frozen-thawed oocytes are known to be
significantly worse than those obtained by fresh oocytes. Little is known about the factors affecting the clinical
outcome of frozen-thawed oocytes. The aim of this retrospective study was to explore the role of oocyte
cryopreservation in the group of patients with no available sperm on the day of in vitro fertilization. Additionally,
the effects of the female serum FSH level and sperm quality on the clinical outcome of frozen-thawed oocytes
were evaluated.
Methods: Oocytes were slowly frozen and thawed in 22 infertile couples with no sperm or insufficient number of
sperm on the day of in vitro fertilization (IVF). In 9 couples with severe azoospermia or
oligoasthenoteratozoospermia frozen-thawed oocytes were fertilized by autologous sperm of bad quality when
available (Group 1). In 13 couples with non-ejaculation due to psychological stress on the day of classical IVF or
severe azoospermia frozen-thawed oocytes were fertilized by autologous or donated sperm of normal quality
(Group 2). Oocytes were thawed in 23 cycles and microinjected by the autologous or donated sperm, when
available. The clinical outcome of intracytoplasmic sperm injection - ICSI (fertilization, blastocyst, and pregnancy
rates) was compared to the outcome of fresh oocytes of the same group of patients; additionally, the female
serum FSH level and the sperm quality were compared.
Results: In all couples, 70.5% of oocytes survived the freeze-thaw procedure. After ICSI, 61.5% of thawed oocytes
were fertilized. Twenty one% of embryos developed to the blastocyst stage. The pregnancy rates per embryo
transfer and freeze-thaw cycle were 33.3% and 17.4%, respectively. All pregnancies ended in the birth of a baby
without congenital anomalies. In patients with severe azoospermia or oligoasthenoteratozoospermia there was no
statistically significant difference in pregnancy rates per cycle obtained by thawed oocytes vs. fresh oocytes in
previous ICSI cycles (14.2% vs. 13.6%) but there was a higher proportion of abnormal, non-cleaved or triploid
zygotes when frozen-thawed oocytes were microinjected (33.3% vs. 11.8%; P < 0.01). The female serum FSH levels
did not affect the survival and fertilization of frozen-thawed oocytes, but in patients with increased serum FSH level
no pregnancies were achieved. After the complete freeze-thaw cycle, there was a significantly higher fertilization
rate and tendency to higher pregnancy rates per thawing cycle after the microinjection of autologous or donated
sperm of normal quality than autologous sperm of poor quality.
Conclusion: The slow oocyte freezing and thawing is a valuable method when no or insufficient number of sperm
are available on the day of in vitro fertilization. The quality of sperm is an important factor affecting the clinical
outcome achieved by frozen-thawed oocytes.
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Background
The slow freezing method is widely used to freeze
human oocytes, both for fertility preservation and in
routine IVF programmes. After 5 years of storage in
liquid nitrogen, oocytes cryopreserved with a slow cool-
ing-rapid thawing protocol can develop in vitro to the
blastocyst stage and produce a live birth [1].
Clinical results obtained after in vitro fertilization of
slowly frozen-thawed oocytes are known to be signifi-
cantly worse than those obtained with fresh oocytes
[2,3]. Despite this fact, oocyte cryopreservation provides
the pregnancy rate of about 14% per freeze-thaw cycle
and should be offered to patients with surplus oocytes
in cases of inapplicability of embryo cryopreservation
[4]. The success of human oocyte cryopreservation
depends on morphological and biophysical factors that
could influence oocyte survival after thawing [5]. At
slow freezing, oocytes are frozen with a low concentra-
tion of cryoprotectant and may therefore result in a
small amount of intra- and extracellular-ice crystal for-
mation, which can damage them. It has been confirmed
that slow freezing damages some fine structures of the
oocyte, including the meiotic spindle and the zona pel-
lucida. Both the meiotic spindle and the zona pellucida
undergo significant changes during slow freezing proce-
dure [6]. The meiotic spindle becomes thinner and
structurally less organized (lower retardance), whereas
the zona pellucida becomes thicker and its inner layer
looses structural organization, as revealed by polarized
light microscopy [6].
Little is known about the factors affecting the clinical
outcome after using frozen-thawed oocytes in in vitro
fertilization programme. Morphological changes of the
oocyte during freeze-thaw procedure seem to be unre-
lated to the patient’s age or body mass index, but zona
pellucida variations in thickness and retardance are sig-
nificantly related to ovarian responsiveness; patients
with a higher response to gonadotrophins produce
oocytes that are better able to preserve their characteris-
tics after freezing-thawing [6].
The aim of this retrospective study was to explore the
role of oocyte cryopreservation in the group of patients
with no available sperm on the day of in vitro fertiliza-
tion; additionally, the effect of the female serum FSH
levels and sperm quality on the clinical outcome of fro-
zen-thawed oocytes were evaluated.
Methods
In this retrospective study, mature (metaphase II)
oocytes were cryopreserved in couples with no sperm or
insufficient number of sperm to fertilize oocytes on the
day of in vitro fertilization, to be fertilized when sperm
available. In Group 1 couples frozen-thawed oocytes
were fertilized by autologous sperm of bad quality when
available. Their oocytes were cryopreserved, because
there were no sperm due to severe azoospermia or oli-
goasthenoteratozoospermia. In severe azoospermia there
was no or insufficient number of sperm in frozen-
thawed testicular tissue cryopreserved at the time of a
previous diagnostic biopsy. These patients were diag-
nosed with Sertoli Cell Only Syndrome (SCOS) with
focal spermatogenesis or with severe hypospermatogen-
esis. In patients with severe oligoasthenoteratozoosper-
mia there were no sperm in 2 subsequent ejaculates. In
Group II couples frozen-thawed oocytes were fertilized
by autologous or donated sperm of normal quality. In
these couples it was not possible to obtain sperm for
fresh oocyte fertilization on the day of in vitro fertiliza-
tion because of severe psychological stress of normos-
permic partners or severe azoospermia. The semen was
considered normal at the concentration of > 20 million
sperm per milliliter and > 50% of motile sperm accord-
ing to the WHO criteria, and at > 14% of morphologi-
cally normal sperm according to Kruger’s strict criteria.
Cryopreserved oocytes were thawed and fertilized when
sperm were available. In couples of Group 1, thawed
oocytes were microinjected by autologous sperm after
improvement of the semen quality or testicular biopsy.
In couples of Group 2, thawed oocytes were microin-
jected by the fresh autologous sperm of normal quality
obtained on the day of oocyte thawing in couples with a
normospermic partner or by frozen-thawed donated
sperm of normal quality in couples with severe azoos-
permia. Eeach sperm donation cycle was approved by
the Slovenian Assisted Reproduction Authority. This
research was approved by the National Medical Ethics
Committee; participants agreed to participate in the
study by signing an informed consent form.
Ovarian stimulation
For controlled ovarian hyperstimulation we used recom-
binant FSH (Follitropin alfa) (rFSH) (Gonal F; Industria
Farmaceutica Serono S.p.A, Bari, Italy) in combination
with GnRH agonist buserelin (Suprefact; Hoechst AG,
Frankfurt/Main, Germany).
In the GnRH agonist protocol ovarian stimulation was
performed using GnRH agonist buserelin administered
from day 22 of the cycle in a daily dose of 0.6 ml (600 pg)
s.c. After 14 days, pituitary desensitization was checked
by E2 determination and B-mode ultrasound scan. Once
the criteria for desensitization were fulfilled (E2 ≤ 0.05
nmol/l, follicles ≤ 5 mm in diameter and endometrial
thickness ≤ 5 mm), ovarian stimulation with a daily dose
of 225 IU rFSH was started. GnRH agonist administra-
tion was continued until HCG administration. HCG
(Pregnyl; N.V. Organon, Oss, The Netherlands) in a dose
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of 10,000 IU was administered when 3 or more follicles
reached a diameter of 18 mm. Oocyte retrieval was per-
formed 34-36 h after HCG administration.
Slow oocyte freezing
Before freezing, oocytes were denuded in hyaluronidase
(SynVitroHydase, Origio, Denmark) to evaluate their
maturity, and washed 3 times in Flushing Medium
(Origio, Denmark). Up to 2 hours after ultrasound-
guided retrieval, mature - metaphase II oocytes with
extruded polar body were frozen in OocyteFreeze Media
(Origio, Denmark). They were washed in PBS and then
incubated in the Freezing solution 1: 1.5 M propanediol
in PBS for 15 minutes at room temperature and in the
Freezing solution II: 1.5 M propanediol and 0.3 M
sucrose in PBS for 15 minutes at room temperature. All
PBS included human serum albumin and alpha/beta glo-
bulins. At most 2 oocytes were transferred into one
0.3 ml CBS ™ high-security straw (BioSystem, France)
with weighted 40 mm identification rod (BioSystem,
France). Then, they were cooled in the Air Liquide
Machine (France) in liquid nitrogen vapour using the
following programme: from 20°C to -8°C at 2°C/min,
from -8°C to -30°C at 0.3°C/min, and from -30°C to
-150°C at 50°C/min. At -8°C a manual seeding was per-
formed. After cooling, the straws with oocytes were
stored in liquid nitrogen (-196°C) until use.
Rapid oocyte thawing
When used, oocytes were warmed for 40 seconds at the
room temperature. They were subsequently transferred
into 4 thawing OocyteThaw solutions (Origio, Denmark)
- Thawing solution I: 1.5M propanediol and 0.2 M
sucrose in PBS for 5 min at room temperature, Thawing
solution II: 0.5 M propanediol and 0.2 M sucrose in PBS
for 5 min at room temperature, Thawing solution III:
0.2 M sucrose for 10 min at room temperature, Thawing
solution IV: PBS for 10 min at room temperature, and
placed in a CO2-incubator for 10 minutes. All PBS
included human serum albumin and alpha/beta globu-
lins. Then oocytes were transferred into the fresh, pre-
incubated Universal IVF Medium (Origio, Denmark) and
incubated in a CO2-incubator at 6% CO2 in air before
microinjection. Oocytes were considered to have sur-
vived, if they had unchanged morphology, normal-bright
cytoplasm, and zona pellucida of normal appearance.
Degenerated oocytes had abnormal shape, damaged zona
pellucida, and brown cytoplasm.
ICSI
Each thawed oocyte was put into a droplet of Sperm Pre-
paration Medium (Origio, Denmark) under paraffin oil
(Origio, Denmark). Partner’s semen, testicular tissue or
frozen-thawed donated sperm was prepared by the density
gradient centrifugation on a concentration gradient (100%
vs. 40%) of PureSperm (NidaCon, Sweden) and washing in
Sperm Preparation Medium (Origio, Denmark). The pellet
was used to perform ‘swim-up’ technique. Up to 2 hours
after thawing, the microinjection of oocytes was performed
without using the PVP as described elsewhere [7]. After
microinjection, oocytes were washed and transferred into
the Universal IVF Medium.
Fertilization, embryo culture and transfer
The next day, 20 to 24 hours after microinjection the
oocyte fertilization was checked for observation of the
number of pronuclei and polar bodies. Normal diploid
zygotes had 2 pronuclei and 2 polar bodies. Triploid
and not-cleaved zygotes were not used for transfers.
Embryo culture
All embryos were cultured in BlastAssist sequential
media (Origio, Denmark) to the blastocyst stage. On
days 2 and 3 they were cultured in M1 medium and
on days 4 and 5 in M2 medium. On day 5 embryos
were classified according to their developmental stage
into blastocysts, expressing the inner cell mass, tro-
phectoderm, and blastocoele cavity, compacted moru-
lae or arrested embryos. At most 2 embryos at the
blastocyst or morula stage were transferred into the
uterus by the TDT catheter set (CCD, Neuilly, France).
One blastocyst was transferred in couples with only
one embryo developed to the blastocyst stage; when
more embryos developed to the blastocyst stage, two
blastocysts were transferred into the uterus. Embryos
were transfered in a natural or modified natural cycle,
as described elsewhere [8,9]. Supernumerary blasto-
cysts were cryopreserved on day 5 or 6 by slow freez-
ing program [10].
Pregnancy
Biochemical pregnancy was confirmed by the positive
serum beta-HCG test 15 days after the embryo transfer,
and clinical pregnancy by ultrasound scan of gestational
sac and embryo heart beats 14 days after the positive
beta-HCG test. The data on the live births were pro-
vided by the Unit of Obstetrics of our department. The
data about the congenital anomalies of children born
after the fertilization of frozen-thawed oocytes were
retrieved from the medical records of the Unit of Pedia-
trics which performs the systematic follow-up of chil-
dren born after assisted reproduction methods.
Statistics
The correlation between the female serum FSH levels
(normal: < 10 IU/L), and semen quality and the clinical
outcome after using frozen-thawed oocytes was evaluated
by the Pearson and Spearman correlation coefficients.
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Differences between the groups were evaluated by the Chi-
Square test. Statistical significance was set at P < 0.05.
Results
The mean duration of frozen oocyte storage until
thawing was 1 year (min. 0.3 year - max. 2 years). In
23 thawing cycles in 22 couples with the mean female
age 31.7 years (range 27 - 40) 70.5% of oocytes sur-
vived the freeze-thaw procedure (Table 1). After ICSI,
61.5% of thawed oocytes were fertilized and 21% of
embryos developed to the blastocyst stage (Table 1).
In 12 (52%) thawing cycles embryos were transferred
into the uterus and 4 pregnancies were achieved,
yielding a 33.3% pregnancy rate per embryo transfer
and a 17.4% pregnancy rate per freeze-thaw cycle,
respectively. As shown in Table 1, there was a ten-
dency for higher pregnancy rates per embryo transfer
and per thawing cycle in Group 2 couples when com-
pared to Group 1 couples (42.8% and 23.1% vs. 20%
and 11.1%, respectively). All pregnancies were single-
ton and ended in births of babies with no congenital
anomalies.
Table 1 Clinical outcome of oocyte freezing and thawing in patients with no sperm or insufficient number of sperm
on the day of in vitro fertilization
Group 1
Frozen oocytes to be fertilized with autologous
sperm of poor quality in severe azoospermia or
oligoasthenoteratozoospermia
Group 2
Frozen oocytes to be fertilized
with autologous or donated
sperm of normal quality
TOTAL
OOCYTE FREEZING
Patients 9 13 22
Mean female age
(years)
31.3 (range 28-36) 31.9 (range 27-40) 31.7 (range 27 - 40)
Female indications
of infertility
4 (44.4%) 10 (76.9%) 14
Freezing cycles 9 14 23
Frozen metaphase II
oocytes
83 83 166
Mean number of
frozen oocytes per
patient
9.2 (min. 4-max. 14) 6.4 (min. 4-max. 12) 7.2 (min. 4 - max. 14)
OOCYTE THAWING
Patients 9 13 22
Thawing cycles 10 13 23
Thawed metaphase
II oocytes
83 83 166
Thawed metaphase
II oocytes per cycle
8.3 (min. 4-max. 14) 6.4 (min. 4-max. 12) 7.2 (min. 4 - max. 14)
Thawed metaphase
II oocytes per
patient
9.2 (min. 4-max.14) 6.4 (min. 4-max. 12) 7.5 (min. 4 - max. 14)
Survived oocytes 56 (67.5%) 61 (73.5%) 117 (70.5%)
Fertilized oocytes
after ICSI
38 (40.9%) 34 (55.7%) 72 (61.5%)
Embryos 23 34 57
Blastocysts 4 8 12
Blastocyst rate 17.4% 23.5% 21.0%
Embryo transfers (ET) 5 7 12
Double embryo
transfers
4 7 11
Pregnancies 1 3 4
Clinical pregnancy
rate per ET
20.0% 42.8% 33.3%
Clinical pregnancy
rate per thawing
cycle
11.1% 23.1% 17.4%
Birth of a child 1 3 4
All differences between the two groups were not statistically significant.
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As shown in Table 2, in patients with severe azoos-
permia or oligoasthenoteratozoospermia (Group 1)
there were no statistically significant differences in fer-
tilization, blastocyst, and clinical pregnancy rates per
cycle obtained by frozen-thawed oocytes vs. fresh
oocytes in previous ICSI cycles performed over the
time period from 0.3 year to 2.3 years before oocyte
thawing (67.1% vs. 50.0%, 23.5 vs. 25.6%, and 14.2% vs.
13.6%, respectively). However, after the microinjection
of frozen-thawed oocytes, there was a significantly
higher proportion of non-cleaved or triploid zygotes in
comparison with fresh oocytes (33.3% vs. 11.8%; P <
0.01). In 2 from 14 (14.3%) oocyte thawing cycles
patients did not arrive to the embryo transfer because
of non-cleaved or triploid zygotes, whereas in the pre-
vious cycles with fresh oocytes none of patients haven’t
arrive to the embryo transfer because of non-cleaved
or triploid zygotes.
The mean serum FSH level in female patients was 7.4
(min. 4.1-max. 18.0) IU/L. In 18 oocyte thawing cycles
performed in 18 patients with a normal serum FSH
level there was approximately the same oocyte survival
rate than in 4 thawing cycles performed in 3 patients
with increased FSH level (70.4% vs. 67.0%). In patients
with normal and increased serum FSH levels the same
percentage (40%) of thawed oocytes were normally ferti-
lized and developed into the embryos. In patients with
normal serum FSH levels 4 (22,2%) pregnancies were
achieved, whereas none of patients with the increased
serum FSH levels became pregnant.
When in Group 2 patients with severe azoospermia or
oligoasthenoteratozoospermia frozen-thawed oocytes
were microinjected with frozen-thawed donor sperm of
normal quality, the fertilization rate was significantly
higher than after the microinjection of autologous
sperm of poor quality (72.2% vs. 40.9%; P < 0.05) in
Group 1 patients, as shown in Table 3. There was also a
tendency to a higher clinical pregnancy rate after the
microinjection of normal sperm than after the microin-
jection of sperm of poor quality (25.0% vs. 11.1%), as
shown in Table 3. Similarly, in Group 2 patients the
clinical pregnancy rate per freeze-thaw cycle achieved by
the microinjection of autologous sperm of normal qual-
ity was comparable to the microinjection of donated
sperm of normal quality (22.2% vs. 25.0%).
After ICSI of frozen-thawed oocytes, 4 blastocysts
were cryopreserved in 2 patients: in one patient 1 blas-
tocyst and in another one 3 blastocysts. After thawing,
all blastocysts (100%) were survived and were comple-
tely non-damaged according to the morphological
Table 2 Clinical outcome of ICSI using frozen-thawed
oocytes in comparison with fresh oocytes in previous
ICSI cycles in patients with severe azoospermia or
oligoasthenoteratozoospermia
ICSI in patients with severe
azoospermia or
oligoasthenoteratozoospermia
Fresh
oocytes
Frozen-thawed
oocytes
Patients 13 13
ICSI cycles 22 14
Injected oocytes 171 111
Fertilized oocytes 85 (50.0%) 51 (67.1%)
Non-cleaved or triploid
zygotes
10 (11.8%)* 17 (33.3%)*
Embryos 78 34
Blastocysts 20 8
Blastocyst rate 25.6% 23.5%
Embryo transfers (ET) 18 7
Pregnancies 3 2
Clinical pregnancy rate per ET 17.0% 28.6%
Clinical pregnancy rate per
cycle
13.6% 14.2%
Birth of a child 3 2
*Statistically significant difference as evaluated by the Chi-Square test at
P < 0.01.
Table 3 Clinical outcome of injection of frozen-thawed
donor sperm of normal quality vs. autologous fresh
sperm of poor quality into frozen-thawed oocytes
ICSI of frozen-thawed oocytes in couples with
severe azoospermia or
oligoasthenoteratozoospermia
DONOR SPERM
(normal quality)
AUTOLOGOUS
EJACULATED OR
TESTICULAR SPERM (poor
quality)
Patients 4 9
ICSI cycles 4 10
Mean female
age (years)
31.2 (range 28 - 38) 31.1 (range 28 - 37)
Injected oocytes 18 93
Fertilized
oocytes
13 (72.2%)* 38 (40.9%)*
Embryos 11 23
Blastocysts 4 4
Blastocyst rate 36.4% 17.4%
Embryo transfers
(ET)
2 5
Pregnancies 1 1
Clinical
pregnancy rate
per ET
50.0% 20.0%
Clinical
pregnancy rate
per thawing
cycle
25.0% 11.1%
Birth of a child 1 1
*Statistically significant difference as evaluated by the Chi-Square test at
P < 0.05.
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criteria. All thawed blastocysts were transferred into the
uterus, but both patients did not become pregnant.
Discussion
The results of this study show that the slow oocyte
freezing and thawing is a valuable method in patients
with no or insufficient number of sperm available on
the day of in vitro fertilization.
In this study, mature oocytes were frozen for up to
2 hours after the ultrasound-guided oocyte retrieval. In
line with other researchers, mature oocytes which were
slowly frozen within this time period yielded a higher
amount of good quality embryos after ICSI than oocytes,
slowly frozen beyond that time period [11]. The time at
which oocyte cryopreservation is performed plays a key
role in the clinical outcome of frozen-thawed oocytes
and should be performed at less than 40 hours after
HCG administration [12]. Cryoprotectant 1,2-propane-
diol and increased concentration 0.3 M sucrose were
used to optimize the oocyte slow freezing procedure [5].
In all patients included into this study, an overall
33.3% pregnancy rate per embryo transfer and a 17.4%
pregnancy rate per thaw cycle were obtained. These
pregnancy rates could be compared to the results of
other groups performing slow oocyte freezing [4,13,14].
Albani et al. reported that the pregnancy and implanta-
tion rates achieved by slowly frozen and thawed oocytes
steadily improved from respectively 6.7% and 2.4% in
2001 to 15% and 8.2% in 2007 [15]. The results of this
study showed that the results after slow oocyte freezing
and thawing were better after fertilization of thawed
oocytes by autologous or donated sperm of normal
quality than after fertilization by autologous sperm of
bad quality. Pregnancy rates achieved by fertilization of
thawed oocytes by sperm of normal quality were higher
than results reported by other groups [4,13-15]: 23.1%
per thawing cycles by autologous sperm and 25,0% per
thawing cycles by donated sperm thus indicating that
normal sperm quality in male partner or decision for
donated sperm of normal quality is an additional indica-
tion for slow oocyte freezing when no sperm available
on the day of in vitro fertilization. The general data of
this study - pregnancy rates achieved by the frozen-
thawed oocytes allow us to counsel future patients in
our clinical practice who face a similar situation of not
being able to collect sperm on the day of oocyte retrie-
val and in vitro fertilization.
In the group of men with severe azoospermia or oli-
goasthenoteratozoospermia, there was no difference in
the clinical outcome of frozen-thawed oocytes insemi-
nated by ICSI when compared to their previous ICSI
attempts with fresh oocytes. The fertilization and blasto-
cyst rates did not differ between ICSI cycles using fresh
and frozen-thawed oocytes. But, there was a significantly
higher proportion of non-cleaved or triploid zygotes
after insemination of frozen-thawed oocytes by ICSI.
This might be related to the disturbances of oocyte
meiotic spindle and some other disturbances during
slow freezing and thawing procedures as confirmed by
several basic studies in animal models [16-18], and also
in humans [19-22].
In spite of increased percentage of non-cleaved or tri-
ploid zygotes, the normal blastocyst rate, a high preg-
nancy rate per embryo transfer (33.3%), and births of
babies with no congenital anomalies in this study
showed that the negative effect of slow oocyte freezing
and thawing might be expressed at the stage of zygote
(especially non-cleaved), and not later, at the embryo
stage.
The negative effect of increasing female age on the
oocyte and embryo quality has been well established
[23-27], but it should be emphasized that the mean age
of women in the present study was 31.7 years (range
27 - 40), lower than the mean age of our in vitro fertili-
zation program (34.7 years). Molinari et al. have found
that the morphological changes of oocytes during the
freeze-thaw procedure seem to be unrelated to the
patient’s age [6]. But, there are no data available in the
literature on clinical outcomes of slow oocyte freezing
and thawing in older women. We cannot make any con-
clusions about the affect of female age on the outcome
of oocyte freeze-thawing in this study, because included
women were too young. In terms of serum FSH level it
should be noted that most women included in this
study had normal levels of serum FSH levels and had a
normal ovarian response to the hormonal stimulation,
thus providing the possibility to freeze the mean num-
ber of 7.2 mature oocytes per a patient. In women with
normal and increased serum FSH levels the oocyte sur-
vival and fertilization rates after freeze-thawing proce-
dures did not differ significantly. Although in all
patients blastocysts or morulae were transferred, 4 preg-
nancies were achieved in women with normal serum
FSH levels, while none of women with increased serum
FSH levels became pregnant. This might reflect worse
quality of oocytes and embryos in patients with
increased serum FSH levels.
On the other hand we found that the sperm quality
affected the outcome of ICSI using frozen-thawed
oocytes. The results obtained by frozen-thawed oocytes
microinjected with autologous or donated sperm of nor-
mal quality were better than after the microinjection of
autologous sperm of poor quality. It is generally known
that in infertile men, sperm of poor quality are related
to a higher level of impaired DNA integrity (i.e., DNA
fragmentation), which might result in a lower fertiliza-
tion potential, worse embryo development, and sponta-
neous abortion [28,29].
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All neonates, born in this study were normal and did
not have any congenital malformations. Although short
term neonatal outcomes were evaluated in this study,
we do not have long term infant outcomes for these
oocyte thawing cycles. Previous studies suggested that
the incidence of congenital malformations in neonates
after fertilization of frozen-thawed oocytes was not
increased [30]; there was any difference in the occur-
rence of congenital malformations between the live
borns after oocyte slow freezing and naturally conceived
infants. The best way to study long-term outcomes
would be to set up a birth registry which is already in
the works [30].
The results of this study showed, that slow oocyte
freezing and thawing in infertile couples with no
sperm available on the day of in vitro fertilization
seem to be safe methods, expressing their negative
effects at the zygote level and resulting in births of
healthy newborns. New method - oocyte vitrification
results in high pregnancy rates [31-33], and seems to
inflict less damage to spindle integrity and chromo-
some alignment during oocyte cooling [34,35],
although it might pose a problem of due to a very high
concentration of potentially toxic cryoprotectant in the
vitrification solution. It is known, that high concentra-
tions of cryoprotectants could induce in vitro chromo-
somal damage in eukaryotic cells [36]. Some studies
showed that in human oocytes subjected to vitrifica-
tion some histones were modified: H3K9 methylation
and H4K5 acetylation were increased [37]; it was pro-
posed, that both of these histone modifications could
be useful markers to monitor epigenetic perturbations
induced by various experimental vitrification protocols
[37]. Properly controlled follow-up studies of neonatal
outcomes, and child long-term follow-up studies for all
oocyte cryopreservation techniques are needed and
have already been proposed [38].
Slow oocyte freezing and thawing is a valuable method
when no or insufficient number of sperm are available on
the day of in vitro fertilization. The quality of sperm is an
important factor affecting the clinical outcome achieved
by frozen-thawed oocytes. The results of this study allow
us to counsel future patients in our clinical practice who
face a similar situation of not being able to collect sperm
on the day of oocyte retrieval and in vitro fertilization.
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